ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

April 1, 2005

NCI Remains Exception To NIH Authority Over Scientific Counselors

January 27, 1995

Patients Sue Milken, Cancer Centers, Over Prostate Cancer Remedy PC-Spes

February 20, 2004

Obituaries: Keith Amos, Trudy Small, and Kie Kian Ang

June 21, 2013

CTEP Director Friedman Adds To Article On Minority Initiative

March 23, 1990

Yarbro-Chabner Debate Continues

April 29, 1983